Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Study ID
- NCT00327678
- Phase
- PHASE3
- Status
- Completed
Conditions
- Leukemia, Lymphocytic
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 59 Years
- Healthy Volunteers
- Not accepted
Interventions
- Rituximab — DRUG
- Imatinib Mesylate — DRUG
Study Details
This study is a multicenter trial of treatment for young ALL patients. All ALL patients will receive the same steroid pre-phase in order to evaluate sensitivity or resistance. Then, patients will be included into 3 specific trials according to biological features (immunophenotype, cytogenetics, and molecular biology). Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) 2005: * T ALL or B ALL non Ph (N=810 patients planned). * GRAALL 2005 R: B ALL non Ph CD20+ (N=220 patients planned). * GRAAPH 2005: ALL Ph+ (N=270 patients planned)
Key Dates
- Start date
- May 31, 2006
- Status verified
- Mar 2016
- Primary completion
- Apr 30, 2014
- Completion
- Apr 30, 2014
Study Design
- Enrollment
- 1,080 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Primary Outcome Measure
Event free survival for all patients [ Time Frame: January 2014 ]
Related Studies
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)PHASE3 · Recruiting · Loxo Oncology, Inc. · Anaheim, California